GSGonzalez-Mancera Miguel Santiago

Gonzalez-Mancera Miguel Santiago

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gonzalez-Mancera Miguel Santiago has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Hendifar

    Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA , US

    1 shared publication
  • Andrew Siref

    Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center , Los Angeles, CA , US

    1 shared publication
  • Arsen Osipov

    Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles, CA , US

    1 shared publication
  • Ayda N. Rodriguez

    National Blood Bank Colombian Red Cross, Bogotá, Colombia

    1 shared publication
  • Brent K. Larson

    Department of Pathology and Laboratory Medicine Cedars‐Sinai Medical Center Los Angeles California USA

    1 shared publication
  • Carmen Gomez‐Fernandez

    Department of Pathology and Laboratory Medicine University of Miami Miller School of Medicine Miami Florida USA

    1 shared publication

Latest Publications

  • 5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms

    by Miguel S Gonzalez-Mancera, Andrew Siref, Kambiz Kosari, Nicholas Nissen, Srinivas Gaddam, Andrew Hendifar, Arsen Osipov, Kevin Waters, Danielle Hutchings, Maha Guindi, et al.

    Adenocarcinomas of the biliary tract frequently present diagnostic challenges because of their histologic overlap with benign and preinvasive lesions. The molecular profiles of biliary adenocarcinomas vary by anatomical location. Variations in IDH1/2, common in intrahepatic cholangiocarcinoma, can lead to defective production of 5-hydroxymethylcytosine (5-hmC). Limited ancillary studies are available for biliary adenocarcinomas, and loss of 5-hmC staining could serve as a helpful ancillary diagnostic tool for biliary tract malignancies. We evaluated 93 cases—20 benign biliary lesions, 15 preinvasive biliary neoplasms, 46 invasive biliary carcinomas, and 12 pancreatic adenocarcinomas—for 5-hmC staining. Preoperative biopsies from 16 cases of biliary carcinoma were also stained. Sixteen nonneoplastic/reactive bile duct biopsies served as controls. Loss of 5-hmC was seen in 41 of 46 (89.1%) biliary malignancies vs 0 of 20 benign tumors (P < .001), for a sensitivity and specificity of 89.1% and 100%, respectively. Intrahepatic cholangiocarcinoma showed loss of 5-hmC in 11 of 13 (84.6%) cases, similar to the 30 of 33 (90.9%) cases in other biliary adenocarcinomas (P = .61). Similarly, 5-hmC loss was more frequent in distal bile duct adenocarcinomas than in pancreatic ductal adenocarcinomas, at 15 of 17 (88.2%) vs 4 of 12 (33.3%), respectively (P = .0045). There was no difference in the frequency of 5-hmC loss in patients that received neoadjuvant therapy vs those who did not (90.9% vs 88.6%, P > .99). 5-hmC immunohistochemistry in preoperative biopsies was concordant with the resection specimen in 81.3% (13/16) of cases. Loss of 5-hmC is not unique to intrahepatic cholangiocarcinoma among biliary carcinomas, but is a useful diagnostic marker differentiating malignancies of the biliary tree from benign mimics.


  • Risk of malignancy associated with the diagnostic categories proposed by the Papanicolaou Society of Cytopathology for pancreaticobiliary specimens: An institutional experience

    by Miguel S. Gonzalez‐Mancera, Saman S. Ahmadian, Carmen Gomez‐Fernandez, Jaylou Velez‐Torres, Merce Jorda, Monica T. García‐Buitrago

    Background: The guidelines published by the Papanicolaou Society of Cytopathology (PSC) intend to unify the reporting language in pancreaticobiliary specimens and improve communication between cytopathologists and clinicians. The six categories in the system will determine the best management for patients. However, there is limited evidence regarding the risk of malignancy (ROM) associated with each category.Methods: A retrospective search was performed for pancreaticobiliary fine‐needle aspiration (FNA) reports with corresponding surgical follow‐up. Cases were reclassified according to the PSC. The ROM, sensitivity, specificity, positive predictive value, and negative predictive value were calculated for each category.Results: A total of 297 cases were identified and reclassified as: 30 nondiagnostic (category I), 45 negative for malignancy (II), 20 atypical (III), 42 neoplastic: other (IVB), 19 suspicious for malignancy (V), and 141 malignant (VI). The absolute ROM was 10% for category I, 8.9% for category II, 60% for category III, 4.8% for category IV when the neoplasms were not characterized as malignant, and 100% when categorized as malignant; 100% for category V, and 95.7% for category VI. Sensitivity, specificity, positive predictive value, and negative predictive value for neoplasia and malignancy, including categories IV to VI, were 96.6%, 88.4%, 97.5%, and 84.4%, respectively.Conclusions: The categories developed by the PSC stratify the ROM. Aspirates designated as categories V and VI had the highest ROM. Our rate of atypical category complies with the recommended rate of <10%. This scheme provides valuable information to clinicians treating patients with pancreatic lesions.


  • Open Access

    Implementation of an Artificial Intelligence Virtual Character for Smoking Cessation and E-Cigarette Awareness in Adolescents

    by K.H.F.E.M. Santos, N. Hein, M. Zaw, M.S. Gonzalez-Mancera, M. Murthi, R.A. Calderon Candelario, M.A. Campos, M. Mirsaeidi

  • Open Access

    In reply to: CD4+CD8+ Double-positive T lymphocytes: Pitfalls

    by Gonzalez-Mancera Miguel Santiago, Gonzalez John Mario

  • Open Access

    Percentages of CD4+CD8+ double-positive T lymphocytes in the peripheral blood of adults from a blood bank in Bogotá, Colombia

    by Miguel S. Gonzalez - Mancera, Natalia I. Bolaños, Manuel Salamanca, Guillermo A. Orjuela, Ayda N. Rodriguez, John M. Gonzalez

    CD4+CD8+ double-positive T-cells (DPTs) have been classified as a separate T-cell subpopulation, with two main phenotypes: CD4high CD8low and CD4low CD8high. In recent years, the relevance of DPTs in the pathogenesis of infections, tumors, and autoimmune diseases has been recognized. Reference values among healthy individuals remain unknown. Therefore, the aim of this study is to provide a reference value for DPTs in peripheral blood from healthy donors in a blood bank in Bogotá, Colombia, and to determine the activation status using a surface marker. One hundred healthy donors were enrolled in the study. Peripheral blood cells were stained for CD3, CD4, CD8, and CD154 (CD40L), and cellular viability was assessed with 7-aminoactinomycin D and analyzed by flow cytometry. The median value for DPTs was 2.6% (interquartile range=1.70%-3.67%). Women had higher percentages of DPTs than men (3.3% vs. 2.1%). The subpopulation of CD4low CD8high showed higher expression of CD154 than the other T-cell subpopulations. DPT reference values were obtained from blood bank donors. A sex difference was found, and the CD4low CD8high subpopulation had the highest activation marker expression.